Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyDurvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

Although the study did not meet its primary end point, the results of secondary analyses suggested a progression-free survival benefit with durvalumab plus olaparib in patients whose tumors harbor mutations in homologous recombination repair genes.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form